Evidence map›Paper›PMID 38018321›Full record

Observational studyCancer medicine2023

Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.

Chun-Hui Lee, Tzu-Chien Lin, Ming Yao, Liang-Tsai Hsiao, Bor-Sheng Ko, Chia-Jen Liu, Tsai-Yun Chen

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Chun-Hui LeeInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID 0000-0002-5276-9896
Tzu-Chien LinDepartment of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ming YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Liang-Tsai HsiaoDivision of Hematology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Chia-Jen LiuDivision of Hematology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0001-7945-9292
Tsai-Yun ChenDivision of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID 0000-0001-7099-8054
National Cheng Kung University Hospital · TWNational Taiwan University · TWNational Taiwan University Hospital · TWNational Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered for patients with high-risk B-cell lymphoma and relapsed or refractory disease. This study aimed to analyze the long-term follow-up data of patients who underwent allo-HSCT in Taiwan. This was a retrospective observational study using data from the Taiwan Society of Blood and Marrow Transplantation database. A total of 105 patients who underwent allo-HSCT because of high-risk, relapsed, or refractory disease between 2010 and 2019 were included. Forty-five percent of the patients previously underwent autologous stem cell transplantation (ASCT). The median follow-up duration was 18.6 months. The probability of 3-year progression-free survival and overall survival (OS) was 34.5% and 37%, respectively. The probability of 1-year non-relapse mortality was 31.4%, and the major cause was infection (75.8%). The multivariable analysis showed that not in remission at the time of transplantation and the absence of graft-versus-host disease (GVHD) were factors associated with inferior OS. The probability of 3-year OS in patients with diffuse large B-cell lymphoma who underwent allo-HSCT and allo-HSCT after ASCT was 40.2% and 25.2%, respectively. Allo-HSCT could be a salvage therapeutic option for relapsed or refractory B-cell lymphoma. Complete remission at the time of allo-HSCT and the presence of GVHD are independent variables for overall survival.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseHumansRetrospective StudiesTaiwanTransplantation, AutologousTransplantation, HomologousB-cell lymphomacomplete remissiondiffuse large B-cell lymphomahematopoietic stem cell transplantationrelapse and refractory

Identifiers

PMID38018321
PMCPMC10757116
OpenAlexW4389148742

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.